Supriya Lifescience Ltd., a cGMP-compliant and leading manufacturer of Active Pharmaceutical Ingredients (APIs), has been recognised by the Government of Maharashtra for its remarkable contribution to pharmaceutical exports.

Dr. Satish Wagh, Executive Chairman & Whole-Time Director, and Dr. Saloni Wagh, Managing Director of Supriya Lifescience., were felicitated with the Maharashtra State Export Award for the financial years 2022–23 and 2023–24.

The awards were presented by Uday Samant, Minister of Industries & Marathi Language, along with P. Anbalagan (IAS), Secretary (Industries), and Deependra Singh Kushwah (IAS), Development Commissioner (Industries) & Commissioner (Exports), during a ceremony held at Taj Lands’ End, Mumbai, on October 13, 2025.

This recognition underscores Supriya Lifescience’s consistent leadership in pharmaceutical exports and its significant contribution to India’s growing reputation as a trusted global healthcare partner.

With a presence in over 120 countries, the company has built a diversified portfolio encompassing Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDF), and Contract Development and Manufacturing Organisation (CDMO) services. Its backward-integrated manufacturing capabilities and steadfast commitment to quality and regulatory compliance continue to drive its international success.

Expressing his gratitude, Dr. Satish Wagh said, “Receiving the Maharashtra State Export Award for two consecutive years is an immense honour for everyone at Supriya Lifescience. This recognition reaffirms our unwavering commitment to global quality standards, continuous innovation, and the export of reliable, affordable pharmaceutical products to over 100 countries. It is a testament to the dedication of our entire team and our valued stakeholders who share our mission of advancing healthcare worldwide.”

Adding to this, Dr. Saloni Wagh remarked, “This award reinforces our focus on sustainable growth, ethical business practices, and scientific excellence. It motivates us to strengthen our research-driven initiatives, invest in advanced technologies, and make a meaningful impact on global healthcare ecosystems. We remain dedicated to contributing to Maharashtra’s industrial growth and to India’s vision of becoming a dependable partner in global healthcare solutions.”